Lung Cancer |

Efficacy and Safety of Docetaxel Plus Oxaliplatin as First-Line Chemotherapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer FREE TO VIEW

Hee Jung Ban, MD; Hyun Wuk Kang*, MD; Chan Woo Park, MD; Woo Jin Kim, MD; Yong Soo Kwon, MD; In Jae Oh, MD; Kyu Sik Kim, MD; Yu-il Kim, MD; Sung Chul Lim, MD; Young Chul Kim, MD
Author and Funding Information

Department of Pulmonology, Chonnam National University Hwasun Hospital, Hwasun-gun, Jeollanam-do, Republic of Korea

Chest. 2012;142(4_MeetingAbstracts):643A. doi:10.1378/chest.1389562
Text Size: A A A
Published online


SESSION TYPE: Lung Cancer Posters II

PRESENTED ON: Wednesday, October 24, 2012 at 01:30 PM - 02:30 PM

PURPOSE: Platinum-based doublets are recommended as first-line treatment of stage IV non-small-cell lung cancer (NSCLC). Oxaliplatin is more potent than cisplatin, requiring fewer DNA adducts to provide equivalent cytotoxicity. The objective of this study is to evaluate the efficacy and safety of oxaliplatin combined with docetaxel as a first line treatment of stage IV NSCLC.

METHODS: This is prospective, single-center, phase II trial. Patients with chemotherapy-naive NSCLC received docetaxel 60 mg/m2 (day 1) and oxaliplatin 70 mg/m2 (day 2) every 3 weeks for up to 6 cycles. The primary endpoint was objective response rate (ORR) and the secondary endpoints were progression-free survival (PFS), overall survival (OS) and safety. Treatment response was evaluated according to version 1.1 of Response Evaluation Criteria in Solid Tumors.

RESULTS: For this preliminary analysis, 23 patients were enrolled and response evaluation was possible in 21. In response evaluable patients, there were no complete response , 8 partial response , 9 stable disease . ORR was 34.8% and disease control rate was 73.9%. Median PFS was 98 days (95% confidence interval, 71~125) and median OS was not reached. Grade 3-4 toxicities occurred in 22.7% of patients. The most common hematologic and non-hematologic toxicity were neutropenia (6.0%) and hyperglycemia (5.3%). 2 cases of sepsis occured and one of them were killed.

CONCLUSIONS: This study suggests that the combination of oxaliplatin and docetaxel is effective in patients with NSCLC, with reasonable toxicities.

CLINICAL IMPLICATIONS: Oxaliplatin can be the alternative anti-neoplastic agent in patients with advanced or metastatic NSCLC

DISCLOSURE: The following authors have nothing to disclose: Hee Jung Ban, Hyun Wuk Kang, Chan Woo Park, Woo Jin Kim, Yong Soo Kwon, In Jae Oh, Kyu Sik Kim, Yu-il Kim, Sung Chul Lim, Young Chul Kim

No Product/Research Disclosure Information

Department of Pulmonology, Chonnam National University Hwasun Hospital, Hwasun-gun, Jeollanam-do, Republic of Korea




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543